Matthew Rabinowitz Sells 403,462 Shares of Natera Inc (NTRA) Stock
Natera Inc (NASDAQ:NTRA) CEO Matthew Rabinowitz sold 403,462 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $24.90, for a total transaction of $10,046,203.80. Following the completion of the transaction, the chief executive officer now owns 1,701,686 shares of the company’s stock, valued at $42,371,981.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Matthew Rabinowitz also recently made the following trade(s):
- On Tuesday, September 11th, Matthew Rabinowitz sold 185,163 shares of Natera stock. The shares were sold at an average price of $25.13, for a total transaction of $4,653,146.19.
Natera stock traded up $0.41 during mid-day trading on Thursday, hitting $25.39. 1,353,900 shares of the company traded hands, compared to its average volume of 359,722. Natera Inc has a one year low of $8.60 and a one year high of $29.62. The firm has a market cap of $1.53 billion, a PE ratio of -10.36 and a beta of 2.21. The company has a debt-to-equity ratio of -3.32, a current ratio of 1.69 and a quick ratio of 1.56.
A number of institutional investors have recently made changes to their positions in NTRA. Sofinnova Ventures Inc bought a new stake in Natera during the first quarter valued at approximately $28,742,000. Fred Alger Management Inc. bought a new stake in Natera during the second quarter valued at approximately $33,271,000. Millennium Management LLC lifted its position in Natera by 135.5% during the second quarter. Millennium Management LLC now owns 744,598 shares of the medical research company’s stock valued at $14,013,000 after purchasing an additional 428,376 shares during the last quarter. BlackRock Inc. lifted its position in Natera by 19.4% during the second quarter. BlackRock Inc. now owns 2,086,829 shares of the medical research company’s stock valued at $39,274,000 after purchasing an additional 338,766 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Natera by 35.2% during the second quarter. Renaissance Technologies LLC now owns 792,400 shares of the medical research company’s stock valued at $14,913,000 after purchasing an additional 206,471 shares during the last quarter. Institutional investors and hedge funds own 66.31% of the company’s stock.
NTRA has been the subject of a number of analyst reports. Morgan Stanley raised their price objective on shares of Natera from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Monday, June 25th. Piper Jaffray Companies raised their price objective on shares of Natera to $27.00 and gave the company an “overweight” rating in a research report on Thursday, August 9th. Robert W. Baird raised their price objective on shares of Natera from $17.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, June 28th. ValuEngine upgraded shares of Natera from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 22nd. Finally, Craig Hallum set a $23.00 price objective on shares of Natera and gave the company a “positive” rating in a research report on Thursday, June 28th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $23.14.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.